Sana Biotechnology, Inc. (SANA)

Sana Biotechnology's stock has fluctuated due to clinical updates and conference presentations. As of May 7, 2026, the share price was $3.50, a 93.37% increase over the year, but a 16.47% year-to-date decline. Key events include Q4 2025 earnings report with an EPS of -$0.16, presentations at conferences, a strategic collaboration with Mayo Clinic for Type 1 Diabetes, and an oral presentation on preclinical data from in vivo CAR T SG293. Investor focus remains on pipeline progress despite ongoing losses.

There is no specific information available to indicate demand seasonality for Sana Biotechnology, Inc.'s products and services. Demand for its future products would likely be driven by disease prevalence, clinical efficacy, regulatory approvals, and market access, rather than typical seasonal patterns.

Sana Biotechnology, Inc. is a biotechnology company focused on creating and delivering engineered cells as medicines. They operate in the healthcare sector, specifically in drug discovery and biotechnology, developing ex vivo and in vivo cell engineering platforms. Their product candidates target areas like oncology, diabetes, B-cell-mediated autoimmune diseases, and CNS disorders, including SC291, SC262, UP421, and SC451. UP421 is in Phase 1 for Type 1 diabetes, and SC451 is in preclinical trials for the same, aiming for normal blood glucose without insulin or immunosuppression. SG293 and SG299 target B-cell malignancies and autoimmune diseases.

Sana Biotechnology has operations in key biotechnology hubs within the United States. Its corporate office is located in Seattle, Washington, with additional operations in Cambridge, Massachusetts, and South San Francisco, California. A manufacturing facility is being developed in Fremont, California.

Sana Biotechnology's brand reputation has been influenced by strategic adjustments, clinical trial progress, and financial performance. A strategic refocus from cancer to autoimmune diseases and halting development of SC291, along with layoffs, raised questions about stability. Positive clinical data from the UP421 trial boosted market sentiment. However, as a pre-revenue company with negative earnings, Sana faces scrutiny regarding its cash burn. Progress in clinical trials and collaborations contribute positively to its reputation.

Sana Biotechnology's ownership is primarily institutional, with 213 institutional owners holding 168,326,815 shares as of May 6, 2026. Major institutional owners include Fmr Llc, Flagship Pioneering Inc., BlackRock, Inc., and Vanguard Group Inc. CEO Steven Harr owns approximately 3.44% of the company's shares. Retail investors hold approximately 12% of the shares.